Sign In
Buy INO
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
12:09pm, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) br
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
05:24pm, Monday, 01'st Jun 2026
New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDA
INOVIO to Participate in Upcoming Scientific and Investor Conferences
08:05am, Thursday, 28'th May 2026
PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
02:03pm, Monday, 25'th May 2026
Inovio Pharmaceuticals NASDAQ: INO shareholders approved all proposals presented at the company's 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young L
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further high
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms
09:55am, Thursday, 14'th May 2026
Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision for INO-3107 in October. Cost discipline has improved, with operating expen
Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript
09:30pm, Wednesday, 13'th May 2026
Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
04:05pm, Wednesday, 13'th May 2026
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee
Hantavirus cases spark surge in pharma and biotech stocks — here's why
07:53am, Monday, 11'th May 2026
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
INOVIO to Participate in Upcoming Scientific Conferences
08:05am, Friday, 08'th May 2026
PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate
INOVIO to Report First Quarter Financial Results on May 13, 2026
04:05pm, Friday, 01'st May 2026
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
01:36pm, Tuesday, 28'th Apr 2026
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO
03:46pm, Tuesday, 07'th Apr 2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) a
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023
BENSALEM, Pa. , April 07, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-trade
